Key facts
- It has raised $370K; the latest was Later Stage VC ($370K) in Jul 2025.
- Notable investors include US National Science Foundation, Richard King Mellon Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Plexision
- ·The full record, as it builds
Funding rounds
No funding rounds for Plexision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Plexision
Developer of cellular biomarkers and personalized diagnostic tests intended for personalized diagnosis and drug development. The company's platform develops advanced cellular biomarkers and personalized diagnostic tests adaptable to assess disease risk across various immunological disorders, predict drug efficacy for specific patients, and inform dosing recommendations for novel immunological drugs, including rapid six-hour test panels for critical conditions like CMV infection and transplant rejection, enabling the personalized medicine market in solid organ transplantation, infectious diseases, and immunological disorders to improve patient outcomes by providing specific, actionable insights, predicting rejection risks, and assessing immunity levels.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2008
- Employees
- 10
- Website
- plexision.com/
- Ownership
- Privately Held (backing)
Plexision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Plexision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Plexision in its N-PORT filings yet. We sweep new filings monthly.